HK Stock Market Move | SKB BIO (06990) rose over 4% in the morning, as the commercialization of its product matrix scales up. The product sales for the first half of the year doubled compared to the same period last year.

SKB BIO (06990) surged over 4% in midday trading, and as of the time of writing, it rose by 3.64%, priced at HKD 541.5, with a trading volume of HKD 157 million. On the news front, SKB BIO's mid-term performance revealed that its revenue for the first half of the year reached RMB 978 million, an increase of 2.93% year-on-year; the profit attributable to shareholders was RMB 388 million, reversing from a loss to a profit. During this period, the company's product, sac-TMT (), which includes the drug Lukanosat and others, quickly gained market share after being included in the medical insurance scheme. Product sales in the first half of the year reached RMB 657 million, a year-on-year increase of 112%. Industry insiders noted that with the opening of the medical insurance window in 2026, the company's products are entering a full-scale growth cycle. Coupled with the company's efforts to enhance product accessibility, this is expected to drive a strong increase in commercial revenue, and the R&D results accumulated previously are rapidly being converted into operational achievements. It is worth noting that sac-TMT has achieved major endpoints in multiple registrational studies and has garnered the first positive dual-endpoint results from a global Phase III study, forming a strategic landscape that expands from single-drug use to combinations, from later-line to frontline treatments, from China to global markets, and across multiple indications.